NICOLE GRILLI: Open Payments
NPI 1710908694 · HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,137 in 108 payments from 34 companies in 2025. Trend: 2023 $2,101 · 2024 $2,207 · 2025 $2,137
Food & beverage: $2,114Education: $24
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $276 |
| AstraZeneca Pharmaceuticals LP | 12 | $258 |
| Vanda Pharmaceuticals Inc. | 9 | $188 |
| Otsuka America Pharmaceutical, Inc. | 7 | $153 |
| Dexcom, Inc. | 7 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $97 |
| Novo Nordisk Inc | 4 | $79 |
| GlaxoSmithKline, LLC. | 3 | $76 |
| Exact Sciences Corporation | 3 | $71 |
| Phathom Pharmaceuticals, Inc. | 7 | $70 |
Products named: FANAPT, REXULTI, Dexcom G6 Transmitter, AIRSUPRA, VRAYLAR, QULIPTA, CAPLYTA, BEVESPI AEROSPHERE.
Industry payments across CT — which companies pay providers there.
